{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:14:27Z","timestamp":1789600467877,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,20]]},"DOI":"10.7759\/cureus.69824","type":"journal-article","created":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T06:21:42Z","timestamp":1726899702000},"source":"Crossref","is-referenced-by-count":3,"title":["Efficacy of Traditional Anti-lipidemic Drugs in Lowering Lipoprotein(a) Levels: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Mohit","family":"Sinha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafik","family":"Maged","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pakeeza","family":"Tarar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkata Varshitha","family":"Bandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hema Manvi","family":"Koneru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hooria","family":"Sarwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"World Heart Report 2023: Confronting the World\u2019s Number One Killer","year":"2023","unstructured":"World Heart Report 2023. Confronting the World\u2019s Number One Killer. World Heart Federation, Geneva; 2023."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2019.08.014","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"290","year":"2019","unstructured":"2019 ESC\/EAS guidelines for the management of dyslipidaemias. lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019, 290:140-205. 10.1016\/j.atherosclerosis.2019.08.014","journal-title":"Atherosclerosis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.06.046","article-title":"Impact of lipids on cardiovascular health: JACC Health Promotion Series","volume":"72","author":"Ference BA","year":"2018","unstructured":"Ference BA, Graham I, Tokgozoglu L, Catapano AL. Impact of lipids on cardiovascular health: JACC Health Promotion Series. J Am Coll Cardiol. 2018, 72:1141-56. 10.1016\/j.jacc.2018.06.046","journal-title":"J Am Coll Cardiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy862","article-title":"Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin\/kexin type 9 antibody treatment","volume":"40","author":"Stiekema LC","year":"2019","unstructured":"Stiekema LC, Stroes ES, Verweij SL, et al.. Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin\/kexin type 9 antibody treatment. Eur Heart J. 2019, 40:2775-81. 10.1093\/eurheartj\/ehy862","journal-title":"Eur Heart J"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.014711","article-title":"Risks of incident cardiovascular disease associated with concomitant elevations in lipoprotein(a) and low-density lipoprotein cholesterol-the Framingham Heart Study","volume":"9","author":"Afshar M","year":"2020","unstructured":"Afshar M, Rong J, Zhan Y, et al.. Risks of incident cardiovascular disease associated with concomitant elevations in lipoprotein(a) and low-density lipoprotein cholesterol-the Framingham Heart Study. J Am Heart Assoc. 2020, 9:e014711. 10.1161\/JAHA.119.014711","journal-title":"J Am Heart Assoc"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2022.10.004","article-title":"Relationship of low-density lipoprotein-cholesterol and lipoprotein(a) to cardiovascular risk: The Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"363","author":"Rikhi R","year":"2022","unstructured":"Rikhi R, Hammoud A, Ashburn N, et al.. Relationship of low-density lipoprotein-cholesterol and lipoprotein(a) to cardiovascular risk: The Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2022, 363:102-8. 10.1016\/j.atherosclerosis.2022.10.004","journal-title":"Atherosclerosis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.10.044","article-title":"Association of lipoprotein(a) with atherosclerotic plaque progression","volume":"79","author":"Kaiser Y","year":"2022","unstructured":"Kaiser Y, Daghem M, Tzolos E, et al.. Association of lipoprotein(a) with atherosclerotic plaque progression. J Am Coll Cardiol. 2022, 79:223-33. 10.1016\/j.jacc.2021.10.044","journal-title":"J Am Coll Cardiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.5114\/aoms\/141941","article-title":"PoLA\/CFPiP\/PCS\/PSLD\/PSD\/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021","volume":"17","author":"Banach M","year":"2021","unstructured":"Banach M, Burchardt P, Chlebus K, et al.. PoLA\/CFPiP\/PCS\/PSLD\/PSD\/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021. Arch Med Sci. 2021, 17:1447-547. 10.5114\/aoms\/141941","journal-title":"Arch Med Sci"},{"key":"ref9","unstructured":"An Update on Lipoprotein(a). The Latest on Testing, Treatment, and Guideline Recommendations. (2023). Accessed: August 25, 2024: https:\/\/www.acc.org\/latest-in-cardiology\/articles\/2023\/09\/19\/10\/54\/an-update-on-lipoprotein-a."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2020.12.075","article-title":"Relation of first and total recurrent atherosclerotic cardiovascular disease events to increased lipoprotein(a) levels among statin treated adults with cardiovascular disease","volume":"145","author":"Wong ND","year":"2021","unstructured":"Wong ND, Zhao Y, Sung J, Browne A. Relation of first and total recurrent atherosclerotic cardiovascular disease events to increased lipoprotein(a) levels among statin treated adults with cardiovascular disease. Am J Cardiol. 2021, 145:12-7. 10.1016\/j.amjcard.2020.12.075","journal-title":"Am J Cardiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou S","year":"2009","unstructured":"Erqou S, Kaptoge S, Perry PL, et al.. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009, 302:412-23. 10.1001\/jama.2009.1063","journal-title":"JAMA"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA-a scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge C","year":"2019","unstructured":"Baethge C, Goldbeck-Wood S, Mertens S. SANRA-a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019, 4:5. 10.1186\/s41073-019-0064-8","journal-title":"Res Integr Peer Rev"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea BJ","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G, et al.. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017, 358:j4008. 10.1136\/bmj.j4008","journal-title":"BMJ"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.11124\/JBIES-22-00125","article-title":"Revising the JBI quantitative critical appraisal tools to improve their applicability: an overview of methods and the development process","volume":"21","author":"Barker TH","year":"2023","unstructured":"Barker TH, Stone JC, Sears K, et al.. Revising the JBI quantitative critical appraisal tools to improve their applicability: an overview of methods and the development process. JBI Evid Synth. 2023, 21:478-93. 10.11124\/JBIES-22-00125","journal-title":"JBI Evid Synth"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2008.02.029","article-title":"Mechanism of action of niacin","volume":"101","author":"Kamanna VS","year":"2008","unstructured":"Kamanna VS, Kashyap ML. Mechanism of action of niacin. Am J Cardiol. 2008, 101:20B-6B. 10.1016\/j.amjcard.2008.02.029","journal-title":"Am J Cardiol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2450\/2015.0163-15","article-title":"Lipoprotein apheresis for the treatment of elevated circulating levels of lipoprotein(a): a critical literature review","volume":"14","author":"Franchini M","year":"2016","unstructured":"Franchini M, Capuzzo E, Liumbruno GM. Lipoprotein apheresis for the treatment of elevated circulating levels of lipoprotein(a): a critical literature review. Blood Transfus. 2016, 14:413-8. 10.2450\/2015.0163-15","journal-title":"Blood Transfus"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2023.02.033","article-title":"Clinical trial design for lipoprotein(a)-lowering therapies: JACC Focus Seminar 2\/3","volume":"81","author":"Malick WA","year":"2023","unstructured":"Malick WA, Goonewardena SN, Koenig W, Rosenson RS. Clinical trial design for lipoprotein(a)-lowering therapies: JACC Focus Seminar 2\/3. J Am Coll Cardiol. 2023, 81:1633-45. 10.1016\/j.jacc.2023.02.033","journal-title":"J Am Coll Cardiol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events:individual patient-data meta-analysis of statin outcome trials","volume":"392","author":"Willeit P","year":"2018","unstructured":"Willeit P, Ridker PM, Nestel PJ, et al.. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events:individual patient-data meta-analysis of statin outcome trials. Lancet. 2018, 392:1311-20. 10.1016\/S0140-6736(18)31652-0","journal-title":"Lancet"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0870-1","article-title":"Effect of ezetimibe monotherapy on plasma lipoprotein(a) concentrations in patients with primary hypercholesterolemia: a systematic review and meta-analysis of randomized controlled trials","volume":"78","author":"Awad K","year":"2018","unstructured":"Awad K, Mikhailidis DP, Katsiki N, Muntner P, Banach M. Effect of ezetimibe monotherapy on plasma lipoprotein(a) concentrations in patients with primary hypercholesterolemia: a systematic review and meta-analysis of randomized controlled trials. Drugs. 2018, 78:453-62. 10.1007\/s40265-018-0870-1","journal-title":"Drugs"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-36204-7","article-title":"Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials","volume":"8","author":"Sahebkar A","year":"2018","unstructured":"Sahebkar A, Simental-Mend\u00eda LE, Pirro M, et al.. Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials. Sci Rep. 2018, 8:17887. 10.1038\/s41598-018-36204-7","journal-title":"Sci Rep"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-017-0787-7","article-title":"Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials","volume":"15","author":"Sahebkar A","year":"2017","unstructured":"Sahebkar A, Simental-Mend\u00eda LE, Watts GF, Serban MC, Banach M. Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials. BMC Med. 2017, 15:22. 10.1186\/s12916-017-0787-7","journal-title":"BMC Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2016.01.030","article-title":"Supplementation with coenzyme Q10 reduces plasma lipoprotein(a) concentrations but not other lipid indices: a systematic review and meta-analysis","volume":"105","author":"Sahebkar A","year":"2016","unstructured":"Sahebkar A, Simental-Mend\u00eda LE, Stefanutti C, Pirro M. Supplementation with coenzyme Q10 reduces plasma lipoprotein(a) concentrations but not other lipid indices: a systematic review and meta-analysis. Pharmacol Res. 2016, 105:198-209. 10.1016\/j.phrs.2016.01.030","journal-title":"Pharmacol Res"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-018-0876-4","article-title":"The effects of coenzyme Q10 supplementation on lipid profiles among patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials","volume":"17","author":"Jorat MV","year":"2018","unstructured":"Jorat MV, Tabrizi R, Mirhosseini N, et al.. The effects of coenzyme Q10 supplementation on lipid profiles among patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials. Lipids Health Dis. 2018, 17:230. 10.1186\/s12944-018-0876-4","journal-title":"Lipids Health Dis"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.06.051","article-title":"Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL\/High Triglyceride and Impact on Global Health Outcomes)","volume":"62","author":"Albers JJ","year":"2013","unstructured":"Albers JJ, Slee A, O'Brien KD, et al.. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL\/High Triglyceride and Impact on Global Health Outcomes). J Am Coll Cardiol. 2013, 62:1575-9. 10.1016\/j.jacc.2013.06.051","journal-title":"J Am Coll Cardiol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.004406","article-title":"Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin)","volume":"129","author":"Khera AV","year":"2014","unstructured":"Khera AV, Everett BM, Caulfield MP, Hantash FM, Wohlgemuth J, Ridker PM, Mora S. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Circulation. 2014, 129:635-42. 10.1161\/CIRCULATIONAHA.113.004406","journal-title":"Circulation"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.06.052","article-title":"Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers","volume":"57","author":"Arsenault BJ","year":"2011","unstructured":"Arsenault BJ, Barter P, DeMicco DA, et al.. Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers. J Am Coll Cardiol. 2011, 57:63-9. 10.1016\/j.jacc.2010.06.052","journal-title":"J Am Coll Cardiol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.02.041","article-title":"Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial","volume":"53","author":"Fraley AE","year":"2009","unstructured":"Fraley AE, Schwartz GG, Olsson AG, et al.. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial. J Am Coll Cardiol. 2009, 53:2186-96. 10.1016\/j.jacc.2009.02.041","journal-title":"J Am Coll Cardiol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.02.066","article-title":"Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study","volume":"52","author":"Choi SH","year":"2008","unstructured":"Choi SH, Chae A, Miller E, et al.. Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study. J Am Coll Cardiol. 2008, 52:24-32. 10.1016\/j.jacc.2008.02.066","journal-title":"J Am Coll Cardiol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon CP","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, et al.. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015, 372:2387-97. 10.1056\/NEJMoa1410489","journal-title":"N Engl J Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.P065334","article-title":"PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role","volume":"57","author":"Raal FJ","year":"2016","unstructured":"Raal FJ, Giugliano RP, Sabatine MS, et al.. PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role. J Lipid Res. 2016, 57:1086-96. 10.1194\/jlr.P065334","journal-title":"J Lipid Res"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy243","article-title":"Corrigendum to: controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics","volume":"40","year":"2019","unstructured":"Corrigendum to. controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics. Eur Heart J. 2019, 40:58. 10.1093\/eurheartj\/ehy243","journal-title":"Eur Heart J"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute\u00a0coronary syndrome","volume":"75","author":"Bittner VA","year":"2020","unstructured":"Bittner VA, Szarek M, Aylward PE, et al.. Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute\u00a0coronary syndrome. J Am Coll Cardiol. 2020, 75:133-44. 10.1016\/j.jacc.2019.10.057","journal-title":"J Am Coll Cardiol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden WE","year":"2011","unstructured":"Boden WE, Probstfield JL, Anderson T, et al.. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011, 365:2255-67. 10.1056\/NEJMoa1107579","journal-title":"N Engl J Med"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Landray MJ","year":"2014","unstructured":"Landray MJ, Haynes R, Hopewell JC, et al.. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014, 371:203-12. 10.1056\/NEJMoa1300955","journal-title":"N Engl J Med"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease","volume":"387","author":"O'Donoghue ML","year":"2022","unstructured":"O'Donoghue ML, Rosenson RS, Gencer B, et al.. Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease. N Engl J Med. 2022, 387:1855-64. 10.1056\/NEJMoa2211023","journal-title":"N Engl J Med"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas S","year":"2020","unstructured":"Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al.. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020, 382:244-55. 10.1056\/NEJMoa1905239","journal-title":"N Engl J Med"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray KK","year":"2020","unstructured":"Ray KK, Wright RS, Kallend D, et al.. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020, 382:1507-19. 10.1056\/NEJMoa1912387","journal-title":"N Engl J Med"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.031356","article-title":"LPA variants are associated with residual cardiovascular risk in patients receiving statins","volume":"138","author":"Wei WQ","year":"2018","unstructured":"Wei WQ, Li X, Feng Q, et al.. LPA variants are associated with residual cardiovascular risk in patients receiving statins. Circulation. 2018, 138:1839-49. 10.1161\/CIRCULATIONAHA.117.031356","journal-title":"Circulation"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.07.020","article-title":"Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis","volume":"66","author":"Capoulade R","year":"2015","unstructured":"Capoulade R, Chan KL, Yeang C, et al.. Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis. J Am Coll Cardiol. 2015, 66:1236-46. 10.1016\/j.jacc.2015.07.020","journal-title":"J Am Coll Cardiol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.116.307983","article-title":"Lipoprotein apheresis for lipoprotein(a)-associated cardiovascular disease: prospective 5 years of follow-up and apolipoprotein(a) characterization","volume":"36","author":"Roeseler E","year":"2016","unstructured":"Roeseler E, Julius U, Heigl F, et al.. Lipoprotein apheresis for lipoprotein(a)-associated cardiovascular disease: prospective 5 years of follow-up and apolipoprotein(a) characterization. Arterioscler Thromb Vasc Biol. 2016, 36:2019-27. 10.1161\/ATVBAHA.116.307983","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosissup.2012.10.015","article-title":"Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography","volume":"14","author":"Safarova MS","year":"2013","unstructured":"Safarova MS, Ezhov MV, Afanasieva OI, et al.. Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography. Atheroscler Suppl. 2013, 14:93-9. 10.1016\/j.atherosclerosissup.2012.10.015","journal-title":"Atheroscler Suppl"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz310","article-title":"Statin therapy increases lipoprotein(a) levels","volume":"41","author":"Tsimikas S","year":"2020","unstructured":"Tsimikas S, Gordts PL, Nora C, Yeang C, Witztum JL. Statin therapy increases lipoprotein(a) levels. Eur Heart J. 2020, 41:2275-84. 10.1093\/eurheartj\/ehz310","journal-title":"Eur Heart J"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M029769","article-title":"Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice","volume":"53","author":"Chennamsetty I","year":"2012","unstructured":"Chennamsetty I, Kostner KM, Claudel T, et al.. Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice. J Lipid Res. 2012, 53:2405-12. 10.1194\/jlr.M029769","journal-title":"J Lipid Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/291518-efficacy-of-traditional-anti-lipidemic-drugs-in-lowering-lipoproteina-levels-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T06:21:45Z","timestamp":1726899705000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/291518-efficacy-of-traditional-anti-lipidemic-drugs-in-lowering-lipoproteina-levels-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,20]]},"references-count":45,"URL":"https:\/\/doi.org\/10.7759\/cureus.69824","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,20]]}}}